Open AccessExperience of a Single Academic Center Using IL-1 Inhibition for Rare Dermatologic Conditions
Author(s) -
Daniel Gutiérrez,
Erik Peterson,
Katerina Svigos,
Alisa N. Femia,
Andrew G Franks,
Kristen Lo Sicco
Publication year - 2022
Publication title -
journal of drugs in dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.701
H-Index - 62
ISSN - 1545-9616
DOI - 10.36849/jdd.6154
Subject(s) - medicine , anakinra , canakinumab , dermatology , refractory (planetary science) , dermatologic surgery , single center , disease , physics , astrobiology
Evidence-based literature regarding management of rare and severe dermatologic disease is limited. Canakinumab and anakinra, two therapeutics used for inhibiting IL-1 pathways, have seen increased utilization for treatment of refractory dermatoses. We sought to better characterize the breadth of dermatologic conditions for which these medications could be utilized.